EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access · CC BY-NC 4.0

Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy

Xuewei Wu iD, Jingjing You iD, Shuixing Zhang iD, Bin Zhang iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-010330 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Xuewei Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We have read with great interest the recent publication entitled “Pretreatment CT-based Machine Learning Radiomics Model Predicts Response in Unresectable Hepatocellular Carcinoma Treated with Lenvatinib plus PD-1 Inhibitors and Interventional Therapy” by Hua et al.1 Although lenvatinib combined with programmed cell death protein-1 inhibitors and interventional (LPI) therapy can be used as primary treatment options, some patients may still be non-responsive to LPI therapy and experience significant adverse events. However, there are no reliable and accurate biomarkers to predict a patient’s response to LPI therapy. To this end, this study developed and validated a radiomics-based machine learning model to non-invasively predict the efficacy of this triple therapy, and to perform risk stratification in those patients with unresectable hepatocellular carcinoma (HCC). The radiomic model performed similarly to the clinical-radiomics model, suggesting that clinical factors failed to produce incremental value to the radiomics model. It is encouraging to see an article focused on developing treatment response prediction models for targeted patients with HCC. This study offers valuable insights for clinicians on how to use radiomics for making clinical decisions and tailoring individualized treatments for patients with unresectable HCC. While the study’s results are promising, several issues warrant further clarification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesMachine LearningImmune Checkpoint InhibitorsHumansTomography, X-Ray ComputedMaleFemaleAgedMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsRadiomics

Stichwörter der Autor:innen

Hepatocellular CarcinomaImmunotherapy

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
  • Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China xld_Jane_Eyre@126.com.

ORCID-Profile: Xuewei Wu, Jingjing You, Shuixing Zhang, Bin Zhang

Zitieren

APA

Wu, X., You, J., Zhang, S., & Zhang, B. (2024). Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010330

Vancouver

Wu X, You J, Zhang S, Zhang B. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-010330

BibTeX
@article{Wu2024,
  author = {Wu, Xuewei and You, Jingjing and Zhang, Shuixing and Zhang, Bin},
  title = {Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-010330}
}
Kostenlos starten →